AND EXCHANGE COMMISSION
to Section 13 or 15(d) of the
Exchange Act of 1934
of report (Date of earliest event reported): September 21, 2017
name of registrant as specified in its charter)
or other jurisdiction
Third Street, Suite 2241
of principal executive offices)
telephone number, including area code)
Name or former address, if changed since last report)
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
growth company [X]
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
September 21, 2017, Egidio Nascimento, the chief financial officer and the principal financial and accounting officer of VBI Vaccines
Inc. (the “Company”) resigned from all positions with the Company and its subsidiaries, effective as
of the same date.
September 21, 2017, the Company appointed Athena Kartsaklis, who has been the Company’s corporate controller since May 23,
2017, as senior vice president, finance, principal financial and accounting officer and chief compliance officer of the Company,
effective as of the same date. Ms. Kartsaklis will also serve as senior vice president, finance, of all of the Company’s
subsidiaries, and as a director of Variation Biotechnologies Inc., a subsidiary of the Company.
Kartsaklis, 52, is a Canadian chartered professional accountant and U.S. certified public accountant and has over 25 years of
experience in conducting audits and managing financial reporting and reviewing internal controls. Before joining the Company
as corporate controller in May 2017, Ms. Kartsaklis served as a senior vice president of SkyWave Mobile Communications Inc.
since December 2013, managing financial reporting, budget and forecast process and audit and other accounting matters. Ms.
Kartsaklis was the manager, financial reporting at Alterna Savings, Ottawa, Canada, from September 2012, mainly responsible
for financial and administrative reporting. From 1992 to September 2012, Ms. Kartsaklis worked at Deloitte, Hadjipavlou,
Sofianos & Cambanis S.A., Athens Greece (Member of Deloitte & Touche International), and became a partner in 2000,
overseeing and performing audits and advising clients on audit and accounting matters. Ms. Kartsaklis received a bachelor of
commerce degree from Dalhousie University in Halifax, Nova Scotia.
Kartsaklis will receive a salary of CAD$225,000 and target performance bonus up to 15% of her salary.
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
September 26, 2017
and Chief Executive Officer|